PHVS

Pharvaris N.V.

• Simply Wall St·11h ago

  Why Pharvaris (PHVS) Is Up 7.3% And What's Next After Phase 3 Trial Success

• TipRanks·1d ago

  Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Fractyl Health, Inc. (GUTS) and Ascendis Pharma (ASND)

• TipRanks·5d ago

  Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Merck & Company (MRK) and Celldex (CLDX)

• TipRanks·10/12 12:20

  Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Pharvaris (PHVS) and Tenet Healthcare (THC)

• TipRanks·10/09 12:30

  What PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD)

• Benzinga·10/09 07:05

  Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review

• NASDAQ·10/09 06:49

  Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027

• TipRanks·10/08 22:45

  Pharvaris’ deucrictibant shows efficacy in published Phase 3 HAE trial

• Simply Wall St·10/08 08:26

  Pharvaris (PHVS) Is Getting Fresh Attention, What Is Behind It?

• Simply Wall St·10/06 19:21

  Will Real World HAE Study Change Pharvaris Stock Narrative

• TipRanks·10/06 10:25

  Analyst Reiterates Buy on Strong Deucrictibant Data and Undervalued Angioedema Opportunity; Maintains $60 Price Target

• TipRanks·10/05 12:40

  Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB) and Pharvaris (PHVS)

• NASDAQ·10/05 11:02

  Pharvaris Study Shows HAE Patients Prefer Oral Prophylaxis Over Injections

• TipRanks·09/26 02:02

  Pharvaris Insider Move Sparks Fresh Buzz on Wall Street

• TipRanks·09/25 02:01

  Insider Move at Pharvaris Sparks Fresh Investor Attention